We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

This study has been terminated.
(due to financial problems)
ClinicalTrials.gov Identifier:
First Posted: March 12, 2007
Last Update Posted: October 29, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Efstathios Mitsopoulos, Papageorgiou General Hospital

The 1st phase of the study will assess the acute biochemical response of PTH, calcium and phosphorus to orally administered doses of cinacalcet once (60mg) or twice (30mg x 2) per day.

The 2nd phase of the study designed to evaluate the long term effects of cinacalcet on BMD (bone mineral density)and the levels of PTH, calcium, phosphorus as well as its ability to control secondary hyperparathyroidism without simultaneous administration of other vitamin D compounds.

Condition Intervention Phase
Secondary Hyperparathyroidism Drug: cinacalcet Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Efstathios Mitsopoulos, Papageorgiou General Hospital:

Primary Outcome Measures:
  • Effects of cinacalcet on bone mineral density and bone histology in hemodialysis patients [ Time Frame: one year period ]

Enrollment: 15
Study Start Date: July 2006
Intervention Details:
    Drug: cinacalcet
    Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age older than 18 yrs
  • On hemodialysis for at least 3 months (thrice weekly)
  • iPTH >300pg/ml or histological evidence of secondary hyperparathyroidism
  • Calcium > 8.1 mg/dl

Exclusion Criteria:

  • Unstable clinical condition
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00446329

Papageorgiou General Hospital
Thessaloniki, Greece, 56403
Sponsors and Collaborators
Papageorgiou General Hospital
Principal Investigator: Efstathios Mitsopoulos, MD Papageorgiou General Hospital, Thessaloniki, Greece
  More Information

Responsible Party: Efstathios Mitsopoulos, Nephrologist, Papageorgiou General Hospital
ClinicalTrials.gov Identifier: NCT00446329     History of Changes
Other Study ID Numbers: 109/16-01-2007
First Submitted: March 9, 2007
First Posted: March 12, 2007
Last Update Posted: October 29, 2014
Last Verified: October 2014

Additional relevant MeSH terms:
Neoplasm Metastasis
Hyperparathyroidism, Secondary
Neoplastic Processes
Pathologic Processes
Parathyroid Diseases
Endocrine System Diseases
Cinacalcet Hydrochloride
Calcimimetic Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs